Endonovo Therapeutics (ENDV) Non Operating Income (2016 - 2023)
Endonovo Therapeutics has reported Non Operating Income over the past 9 years, most recently at -$293373.0 for Q3 2023.
- Quarterly results put Non Operating Income at -$293373.0 for Q3 2023, down 850.07% from a year ago — trailing twelve months through Sep 2023 was -$15.3 million (down 2517.1% YoY), and the annual figure for FY2022 was -$15.2 million, down 1631.72%.
- Non Operating Income for Q3 2023 was -$293373.0 at Endonovo Therapeutics, down from -$15328.0 in the prior quarter.
- Over the last five years, Non Operating Income for ENDV hit a ceiling of $5.0 million in Q1 2020 and a floor of -$15.0 million in Q4 2022.
- Median Non Operating Income over the past 5 years was -$726616.0 (2021), compared with a mean of -$1.5 million.
- Biggest five-year swings in Non Operating Income: plummeted 1480.6% in 2019 and later surged 414.96% in 2020.
- Endonovo Therapeutics' Non Operating Income stood at -$4.9 million in 2019, then skyrocketed by 72.72% to -$1.3 million in 2020, then soared by 305.75% to $2.8 million in 2021, then crashed by 641.55% to -$15.0 million in 2022, then surged by 98.04% to -$293373.0 in 2023.
- The last three reported values for Non Operating Income were -$293373.0 (Q3 2023), -$15328.0 (Q2 2023), and -$9190.0 (Q1 2023) per Business Quant data.